NanoViricides Inc (NNVC)
AMEXHealth CareBiotechnologySnapshot 2026-09-04
$1.12-2.61%
Close 2026-09-04 · 1-day change
AMEXHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · NNVC
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Continue to raise funds via registered direct offerings with institutional investors to support operations and development.
Stated as a priority in 2 of last 2 quarters. NanoViricides raised approximately $2 million in 2026-Q1 and $3.8 million in 2026-Q3 through registered direct offerings. These capital raises align with management's stated focus on funding operations and development, indicating delivery on this priority.
“NanoViricides announced pricing of ~$3.8 Million Registered Direct Offering”
“NanoViricides Announces Pricing of ~$2 Million Registered Direct Offering”
Control operating losses and cash burn to sustain clinical-stage development activities.
Stated as a priority in 8 of last 8 quarters. Operating income improved from negative $3.17 million in 2025-Q1 to negative $2.03 million in 2026-Q3, and cash from operations improved from negative $2.59 million to negative $1.93 million over the same period. This shows limited progress in managing losses and cash burn, consistent with management's ongoing focus.
“Operating income was negative $2.03 million with cash from operations negative $1.93 million”
“Operating income was negative $2.23 million with cash from operations negative $2.05 million”
“Operating income was negative $1.80 million with cash from operations negative $1.59 million”
“Operating income was negative $2.12 million with cash from operations negative $1.70 million”
“Operating income was negative $2.25 million with cash from operations negative $1.99 million”
“Operating income was negative $2.06 million with cash from operations negative $2.19 million”
“Operating income was negative $3.17 million with cash from operations negative $2.59 million”
“Operating income was negative $2.39 million with cash from operations negative $1.48 million”
Advance clinical development and eventual commercialization of NV-387, a broad-spectrum antiviral with orphan drug designation.
Stated as a priority in 2 of last 2 quarters. Management highlights NV-387's orphan drug designation and broad antiviral efficacy. While no revenue is reported yet, the clinical-stage focus remains consistent with management's stated product development priority.
“NV-387 has been granted an Orphan Drug Designation by the US FDA and is effective in lethal animal infection models”
“NV-387 is a revolutionary antiviral drug offered at first visit for respiratory viral illness”
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13363).
Over the trailing year it converted 0.66x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to real (inflation-adjusted) rates, the US dollar, long-term interest rates, Fed net liquidity (low R² over the window).
6 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated neutral grew net income 53% of the time over the next year (vs 49% for the rest of the cohort, n=5275).
Not investment advice. As of 2026-09-04.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.